About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research conducted in our group is geared toward elucidating the cause and molecular mechanisms of neurodegeneration in Parkinson's disease (PD), a disabling, currently incurable common neurodegenerative disorder. To this end, we perform clinical and pre-clinical translational research in both PD patients and in human-relevant experimental in vitro and in vivo PD-related models.
Elucidating the molecular mechanisms underlying neurodegeneration in PD should allow to:
PMID: 37923826 Journal: DIGESTIVE DISEASES AND SCIENCES Year: 2023 Reference: Dig Dis Sci. 2023 Nov 3. doi: 10.1007/s10620-023-08155-1. Impact factor: Publication type: Paper in international publication Authors: Belohlavek, Jan; Dimitrova, Emiliya; Elenski, Kiril; Etropolska, Zlatka; Jung, Christian; Petrisor, Diana Corina; Riera, Jordi; Santos, Javier et al. DOI: 10.1007/s10620-023-08155-1
PMID: 37943110 Journal: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Year: 2023 Reference: Am J Respir Crit Care Med. 2023 Nov 9. doi: 10.1164/rccm.202305-0896OC. Impact factor: Publication type: Paper in international publication Authors: Agerstrand, Cara; Ait Hssain, Ali; Arcadipane, Antonio; Balik, Martin; Beggs, Alan; Ben Yaou, Rabah; Bertini, Enrico Silvio; Bloch, Adrien; Boespflug-Tanguy, Odile; Bonne, Gisele et al. DOI: 10.1164/rccm.202305-0896OC
PMID: 37945774 Journal: Nature Reviews Rheumatology Year: 2023 Reference: Nat Rev Rheumatol. 2023 Nov 9. doi: 10.1038/s41584-023-01045-w. Impact factor: Publication type: Paper in international publication Authors: Aggarwal, Rohit; Alonso Losada, Maria G; Alonso Redondo, Ruben; Alvarado, Maria Cristina Iniguez; Alvarez Sauco, Maria; Avila Rivera, Maria A; Borrue, Carmen; Buongiorno, Maria Teresa; Caballol, Nuria; Cabo, Iria et al. DOI: 10.1038/s41584-023-01045-w
PMID: 37949696 Journal: SURGERY Year: 2023 Reference: Surgery. 2023 Nov 8:S0039-6060(23)00708-0. doi: 10.1016/j.surg.2023.09.038. Impact factor: Publication type: Paper in international publication Authors: Agerstrand, Cara; Ait Hssain, Ali; Arcadipane, Antonio; Balik, Martin; Brodie, Daniel; Broman, Lars Mikael; Buabbas, Sara; Buscher, Hergen; Chico, Juan I; Combes, Alain et al. DOI: 10.1016/j.surg.2023.09.038
PMID: 33242731 Journal: JOURNAL OF AFFECTIVE DISORDERS Year: 2021 Reference: J Affect Disord. 2021 Feb 1;280(Pt B):77-89. doi: 10.1016/j.jad.2020.11.075. Epub 2020 Nov 13. Impact factor: Publication type: Paper in international publication Authors: Alonso Losada, M G; Borrue, C; Caballol, N; Cabo-Lopez, I; Carrillo Padilla, F; Cores Bartolome, C; Cubo, E; de Deus Fonticoba, T; Garcia Caldentey, J; Gonzalez Aramburu, I et al. DOI: 10.1016/j.jad.2020.11.075
PMID: 34778332 Journal: Frontiers in Nutrition Year: 2021 Reference: Front Nutr. 2021 Oct 28;8:718093. doi: 10.3389/fnut.2021.718093. eCollection 2021. Impact factor: 6.576 Publication type: Review in international publication Authors: Fortea, Marina, Albert-Bayo, Merce, Abril-Gil, Mar, Ganda Mall, John-Peter, Serra-Ruiz, Xavier, Henao-Paez, Alejandro, Exposito, Elba, Gonzalez-Castro, Ana Maria, Guagnozzi, Danila, Lobo, Beatriz et al. DOI: 10.3389/fnut.2021.718093
PMID: 33986284 Journal: npj Parkinsons Disease Year: 2021 Reference: NPJ Parkinsons Dis. 2021 May 13;7(1):40. doi: 10.1038/s41531-021-00184-9. Impact factor: 8.651 Publication type: Paper in international publication Authors: Yanes, Oscar, Laguna, Ariadna, Xicoy, Helena, Tolosa, Eduardo, Serradell, Monica, Vilas, Dolores, Gaig, Carles, Fernandez, Manel, Iranzo, Alex, Vila, Miquel et al. DOI: 10.1038/s41531-021-00184-9
PMID: 33875401 Journal: Revista Espanola de Medicina Nuclear e Imagen Molecular Year: 2021 Reference: Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021 Apr 16. pii: S2253-654X(21)00057-3. doi: 10.1016/j.remn.2021.02.015. Impact factor: 1.359 Publication type: Letter or abstract Authors: Hernandez-Vara, J, Martinez-Saez, E, Lucas Del Pozo, S, Cardozo-Saavedra, A, Carrillo-Villamizar, E, Lorenzo-Bosquet, C et al. DOI: 10.1016/j.remn.2021.02.015
The initiative seeks to raise awareness of the disease and promote the well-being of those affected, while fostering empathy and scientific vocations among young people.
On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.
Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.
Vall d'Hebron Iniciativa per al Parkinson (VHIP) is a research project aimed at the development of biochemical markers for the early detection of Parkinson's disease. This study is carried out in people at high risk of having this disease, because they carry genetic mutations that predispose to the development of Parkinson's or because they present non-motor symptoms that manifest themselves years before motor symptoms.
